SEC Form 4 · accession 0001209191-15-075707

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 14, 2015

Accepted (ET)

Oct 16, 2015 · 3:31 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 14, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Oct 14, 2015	S	900	$110.58	D	354,784	D
Common Stock^F2,F4	Oct 14, 2015	S	2,676	$111.76	D	352,108	D
Common Stock^F2,F5	Oct 14, 2015	S	3,924	$112.81	D	348,184	D
Common Stock^F2,F6	Oct 14, 2015	S	2,500	$113.64	D	345,684	D
Common Stock^F2,F7	Oct 14, 2015	S	400	$114.60	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$35.64	Oct 14, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	156,800	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $110.58 (range $110.15 to $110.86).
F4Open market sales reported on this line occurred at a weighted average price of $111.76 (range $111.24 to $112.20).
F5Open market sales reported on this line occurred at a weighted average price of $112.81 (range $112.29 to $113.25).
F6Open market sales reported on this line occurred at a weighted average price of $113.64 (range $113.30 to $114.10).
F7Open market sales reported on this line occurred at a weighted average price of $114.60 (range $114.40 to $114.84).
F8Fully vested.